What a 503A Compounding Pharmacy Is
Educational content only. Not medical advice. FeelGood does not claim that any peptide treats, cures, prevents, or mitigates any disease or condition. Consult a qualified healthcare provider before making any decisions about peptide therapy.
A 503A compounding pharmacy is a state-licensed pharmacy where a licensed pharmacist or physician prepares a customized medication for an individual patient who holds a valid prescription. It operates under Section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded drugs are not FDA-approved, and the pharmacy answers primarily to its state board of pharmacy.[1][2]
This sits within the wider question of peptide legality. For how United States law treats peptides overall, see the overview on whether peptides are legal.
503A versus 503B: the core difference
Federal law splits pharmacy compounding into two regulatory tracks. Section 503A covers the traditional pharmacy that compounds against a prescription for a named patient. Section 503B, added in 2013, created a second category called the outsourcing facility, which compounds at larger scale and supplies healthcare facilities. The two categories carry different obligations, and the contrast is the fastest way to understand what 503A is.[2][3]
- Primary regulator. 503A compounding pharmacy: State board of pharmacy. 503B outsourcing facility: FDA, with state oversight.
- Patient-specific prescription. 503A compounding pharmacy: Required. 503B outsourcing facility: Not required; may compound for office stock.
- Manufacturing standard. 503A compounding pharmacy: USP compounding chapters; exempt from cGMP. 503B outsourcing facility: Full cGMP compliance.
- Scale and distribution. 503A compounding pharmacy: Individual prescriptions, largely intrastate. 503B outsourcing facility: Larger batches, interstate distribution permitted.
- Who it serves. 503A compounding pharmacy: An identified patient. 503B outsourcing facility: Hospitals, clinics, healthcare providers.
- FDA registration. 503A compounding pharmacy: Not required to register as an outsourcing facility. 503B outsourcing facility: Must register with FDA and undergo inspection.
The exemptions are the legal heart of the distinction. A drug compounded under Section 503A is exempt from three requirements that apply to manufactured drugs: current good manufacturing practice under section 501(a)(2)(B), the labeling rules for adequate directions for use under section 502(f)(1), and premarket approval through a new drug application under section 505.[4] Those exemptions exist because a 503A pharmacy makes a medication for one patient at a time rather than mass-producing a standardized product.
How Section 503A fits in the law
Pharmacy compounding predates the modern FDA. For most of the twentieth century, it was regulated almost entirely by the states. Federal involvement arrived in stages.
The first was the FDA Modernization Act of 1997, which added Section 503A to the Federal Food, Drug, and Cosmetic Act. The provision codified the conditions under which a compounded drug would be exempt from federal manufacturing, labeling, and approval requirements. Parts of the original statute were later challenged on First Amendment grounds over its advertising restrictions, which left the provision in legal uncertainty for several years.[2]
The second stage followed a 2012 fungal meningitis outbreak traced to contaminated compounded injections produced by a single compounding pharmacy. Congress responded with the Drug Quality and Security Act of 2013. The law clarified Section 503A and created Section 503B, the outsourcing-facility category, giving the FDA a direct oversight path for compounders operating at manufacturing scale.[2][3] Section 503A now sits at 21 U.S.C. 353a, and Section 503B at 21 U.S.C. 353b.[4]
What a 503A pharmacy may compound, and the bulk drug substances list
A 503A pharmacy cannot compound from any raw ingredient it chooses. The active pharmaceutical ingredient, which the statute calls a bulk drug substance, must satisfy one of three conditions. It must comply with an applicable United States Pharmacopeia or National Formulary monograph if one exists. If no monograph exists, it must be a component of an FDA-approved drug. If neither applies, it must appear on a list the FDA develops by regulation, known as the 503A bulks list.[4]
Building that list is an ongoing process. While the FDA evaluates nominated substances, it operates under an interim policy and sorts each nominated substance into one of three categories.[5][6]
- Category 1 holds substances with sufficient supporting information and no immediate safety concern. These may be used in compounding while the agency completes its review.
- Category 2 holds substances the FDA has identified as raising significant safety concerns. These may not be compounded.
- Category 3 holds substances nominated without adequate supporting data. These may not be compounded either.
In January 2025, the FDA finalized interim guidance that stopped the categorization process for substances nominated on or after the guidance date and committed the agency to resolving the remaining list through formal rulemaking.[5][6] Several peptides reached the interim list through earlier nominations. The supply-chain background to those nominations is covered in a separate article on peptide sourcing and the supply chain.
The current focus is a Pharmacy Compounding Advisory Committee meeting scheduled for July 23 and 24, 2026, under docket FDA-2025-N-6895.[7] The committee, known as PCAC, will review seven peptides nominated for the Section 503A bulks list. On the first day it will consider BPC-157, KPV, TB-500, and MOTS-C. On the second day it will consider Emideltide, also called delta sleep-inducing peptide, along with Semax and Epitalon.[7] The public comment docket closes July 22, 2026, and comments received by July 9, 2026, are provided to the committee.[7] The agenda is examined in detail in a separate article on the July 2026 PCAC review. The committee's recommendations are advisory. Any change to a peptide's compounding status follows separately through the rulemaking the FDA has said it will use to finalize the list.[5]
The quality standards: USP 795, 797, and 800
Although 503A pharmacies are exempt from cGMP, they are not unregulated on quality. They follow the compounding chapters of the United States Pharmacopeia, the standards-setting body whose monographs the FD&C Act references directly.[4] Three chapters carry most of the weight.
USP General Chapter 795 governs the compounding of nonsterile preparations, such as capsules, creams, and oral liquids. It sets requirements for ingredients, documentation, and the beyond-use date, which is the date after which a compounded preparation should no longer be used. USP General Chapter 797 governs sterile compounding, including injectable preparations, and addresses the engineering controls, environmental monitoring, and personnel practices that limit microbial contamination. USP General Chapter 800 governs hazardous drugs and the handling practices that protect personnel and the environment from exposure.[1] State boards of pharmacy decide how far to enforce these chapters, and adoption has historically varied from state to state.[1]
State boards of pharmacy and FDA oversight
Oversight of a 503A pharmacy is shared, and the division of labor explains much of how the category works in practice. The state board of pharmacy is the primary regulator. It licenses the pharmacy, inspects it, and enforces pharmacy practice standards within its borders.[1][2] The FDA retains authority over specific federal questions, including whether a pharmacy has crossed from patient-specific compounding into manufacturing, whether it used an unapproved bulk substance, and whether its products are adulterated or misbranded.[2]
One distinction matters more than any other for a reader trying to interpret claims in this market. A drug compounded at a 503A pharmacy is not FDA-approved. The FDA does not review compounded drugs for safety or effectiveness before they reach a patient, and the statutory exemption from premarket approval is precisely what defines the category.[2][4] A pharmacy may be state-licensed, and a bulk substance may have been manufactured at an FDA-registered facility, but neither condition is the same as FDA approval of the finished compounded drug. The phrase "FDA-registered" describes a facility's administrative status, not an endorsement of a product.
503A and peptides
For peptides, the practical question is which regulatory pathway, if any, allows a given compound to be compounded at a 503A pharmacy at a given time. The answer follows the bulk drug substances framework rather than any property of the molecule itself. A peptide may be compounded under Section 503A only if it satisfies one of the statutory conditions for a bulk drug substance, which for most peptides means appearing in an eligible category on the interim bulks list or, eventually, on the finalized list.[4][5]
That status is unsettled and moving. The seven peptides scheduled for the July 2026 PCAC meeting are under active review, and the committee's recommendations will feed the FDA's rulemaking rather than settle the matter on their own.[5][7] Legal analyses of the January 2025 interim guidance note that the categorization process has tightened and that interim eligibility does not equal a final determination.[6] Any compounded peptide preparation that does reach a patient does so through a 503A or 503B pathway, against a prescription where Section 503A applies, and remains a compounded drug rather than an FDA-approved one.[2][4] FeelGood tracks these developments as regulatory facts, without representing any peptide's status as settled ahead of the FDA's own process.
Frequently asked questions
What is a 503A compounding pharmacy?
A 503A compounding pharmacy is a state-licensed pharmacy where a licensed pharmacist or physician prepares a customized medication for an individual patient with a valid prescription, under Section 503A of the Federal Food, Drug, and Cosmetic Act. Its compounded preparations are exempt from FDA premarket approval, cGMP, and certain labeling rules, and its primary regulator is the state board of pharmacy rather than the FDA.[2][4]
What is the difference between a 503A and a 503B pharmacy?
A 503A pharmacy compounds against a prescription for an individual, identified patient and is overseen mainly by its state board of pharmacy. A 503B outsourcing facility, created by the Drug Quality and Security Act of 2013, may compound larger batches without patient-specific prescriptions, supplies healthcare facilities, must register with the FDA, and must comply with current good manufacturing practice.[2][3]
Who regulates 503A compounding pharmacies?
State boards of pharmacy are the primary regulators of 503A pharmacies, handling licensing, inspection, and pharmacy practice standards. The FDA retains authority over federal questions, including the use of unapproved bulk drug substances, whether a pharmacy has shifted into manufacturing, and whether products are adulterated or misbranded. Oversight is shared between the two.[1][2]
What is the 503A bulk drug substances list?
The 503A bulk drug substances list is the FDA-developed list of active ingredients that a 503A pharmacy may use when no applicable USP or National Formulary monograph exists and the substance is not a component of an FDA-approved drug. While the agency builds the list, it runs an interim policy that sorts nominated substances into Category 1, which may be compounded, and Categories 2 and 3, which may not.[4][5]
Is a 503A compounding pharmacy FDA-approved?
No. Drugs compounded at a 503A pharmacy are not FDA-approved. The FDA does not review compounded preparations for safety or effectiveness before they reach patients, and the statutory exemption from premarket approval defines the category. A pharmacy may be state-licensed and use ingredients from FDA-registered facilities, but that is not the same as FDA approval of the finished compounded drug.[2][4]
What standards must a 503A pharmacy follow?
A 503A pharmacy follows the United States Pharmacopeia compounding chapters even though it is exempt from cGMP. USP General Chapter 795 covers nonsterile compounding, USP General Chapter 797 covers sterile compounding, and USP General Chapter 800 covers hazardous drugs. These chapters address ingredients, beyond-use dates, environmental controls, and personnel practices. State boards of pharmacy determine the extent of enforcement.[1][4]
Footnotes
[1] National Academies of Sciences, Engineering, and Medicine. "Regulatory Framework for Compounded Preparations," in The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. National Academies Press, 2020. NCBI Bookshelf NBK562888. https://www.ncbi.nlm.nih.gov/books/NBK562888/
[2] U.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers." https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
[3] U.S. Congress. Drug Quality and Security Act, Public Law 113-54, 2013. https://www.congress.gov/bill/113th-congress/house-bill/3204
[4] U.S. Food and Drug Administration. "Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry," 2016. https://www.fda.gov/files/drugs/published/Pharmacy-Compounding-of-Human-Drug-Products-Under-Section-503A-of-the-Federal-Food--Drug--and-Cosmetic-Act-Guidance.pdf
[5] U.S. Food and Drug Administration. "Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry," finalized January 2025. Federal Register, January 7, 2025 (90 FR 1198). https://www.federalregister.gov/documents/2025/01/07/2024-31546/interim-policy-on-compounding-using-bulk-drug-substances-under-section-503a-of-the-federal-food-drug
[6] Frier Levitt. "Pharmacy Alert: FDA Issues Final Interim Guidances on Compounding Using Bulk Drug Substances," 2025. https://www.frierlevitt.com/articles/pharmacy-alert-fda-issues-final-interim-guidances-on-compounding-using-bulk-drug-substances/
[7] U.S. Food and Drug Administration. "Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments." Docket FDA-2025-N-6895, Federal Register, April 16, 2026 (FR Doc. 2026-07361). https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request